Waycross Partners’s Exact Sciences EXAS Stock Holding History

Waycross Partners’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$1.37M	–	95
2025 Q3	$1.37M	Hold	25,000	–	–	0.12%	52
2025 Q2	$1.33M	Buy	+25,000	New	+$1.27M	0.13%	51

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Waycross Partners's EXAS Position: Q4 2025 in Review

Waycross Partners sold out of Exact Sciences (EXAS) in Q4 2025, closing a stake of 25,000 shares — an estimated $1.37M sold.

Waycross Partners first reported a position in EXAS in Q2 2025 and held it in 2 quarters. The position peaked at $1.37M in Q3 2025. 711 funds tracked by Wall St. Rank hold EXAS as of Q4 2025.

Waycross Partners reported no remaining Exact Sciences position as of Q4 2025 after selling out during the quarter.
Waycross Partners sold 25,000 Exact Sciences shares in Q4 2025, an estimated $1.37M.
Waycross Partners first reported a position in Exact Sciences in Q2 2025 and held it in 2 quarters.
Waycross Partners's Exact Sciences position peaked at $1.37M in Q3 2025.
711 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2025.

Based on Waycross Partners's 13F filing for Q4 2025, filed 14 Jan 2026.